Evaluation of Ixazomib, Lenalidomide, Dexamethasone Induction and extended Consolidation followed by Lenalidomide Maintenance in Newly Diagnosed Multiple Myeloma Patients ≤65 years eligible for High Dose Therapy: a phase II study of the Intergroup Francophone Myeloma (IFM)
Phase of Trial: Phase II
Latest Information Update: 18 Jul 2017
At a glance
- Drugs Ixazomib (Primary) ; Lenalidomide (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Therapeutic Use
- 11 Jul 2017 Planned End Date changed from 1 Mar 2021 to 1 Apr 2021.
- 11 Jul 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Apr 2018.
- 11 Jul 2017 Status changed from not yet recruiting to recruiting.